News | Antiplatelet and Anticoagulation Therapies | July 25, 2017

Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice

British researchers find general practitioners are equally likely to prescribe anticoagulants to people without atrial fibrillation as those with it

Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice

July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

The study, published in the British Journal of General Practice, was carried out by researchers at the University of Birmingham’s Institute of Applied Health Research.

Best practice guidelines recommend anticoagulant drugs such as warfarin are prescribed to patients with atrial fibrillation (AF), a heart condition that causes an irregular heartbeat.

First author Nicola Adderley, Ph.D., said, “These patients are at high risk of stroke and anticoagulant drugs greatly reduce the stroke risk as they make blood less likely to clot.

“However, because they reduce blood clotting, patients taking anticoagulant drugs are at risk of bleeding complications.

“Therefore, safety advice is to avoid anticoagulants in patients who have certain conditions such as a bleeding peptic ulcer, diabetic eye disease or a previous stroke caused by a bleed.”

The researchers reviewed patient records from 645 general practices over a 12-year period between 2004 and 2015. They found that AF patients with conditions making them a safety risk and those without safety risks were almost equally likely to be prescribed anticoagulants. The situation did not change over time.

Corresponding author Prof. Tom Marshall, Ph.D., said, “Our study shows that safety advice seems not to influence the prescribing of anticoagulants. We found that patients considered a safety risk were just as likely to be prescribed the drugs as those without safety risks, and this occurred in every year between 2004 and 2015.

“Because anticoagulants prevent strokes in people with this type of irregular pulse, GPs are encouraged to prescribe more anticoagulants to those who need them. This has been happening and it is good news. But the sting in the tail is that more people who perhaps shouldn’t be on anticoagulants are also taking them: about 38,000 nationally.

“We need to understand the reasons for this and whether patients might come to any harm,” he said.

For more information: www.bjgp.org

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init